Application of UV-derivative spectra for determination of four antihyperlipidaemic drugs in pharmaceutical formulations.
A method for the determination of bezafibrate, ciprofibrate, fenofibrate and gemfibrozil in pharmaceutical formulations by first-, second- and third- derivative spectrophotometry is described, using "peak-peak" and "peak-zero" measurements. The calibration graphs were linear in the range 2-20 microg x mL(-1) for all the compounds investigated. No interference was found from tablet excipients at the selected wavelengths and assay conditions. The developed methods were found to be validated and showed good precision and reproducibility (RSD = 1.57%, 0.78%, 1.45%, and 1.36%, respectively).
Komsta
Lukasz
L
Department of Medicinal Chemistry Medical University of Lublin 6 Chodiki Str., 20-093 Lublin, Poland.
Misztal
Genowefa
G
D001629:Bezafibrate / Q000032:analysis; D002138:Calibration; D002214:Capsules; D002626:Chemistry, Pharmaceutical; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000032:analysis; D011345:Fenofibrate / Q000032:analysis; D058607:Fibric Acids; D015248:Gemfibrozil / Q000032:analysis; D000960:Hypolipidemic Agents / Q000032:analysis*; D007202:Indicators and Reagents; D012997:Solvents; D013056:Spectrophotometry, Ultraviolet; D013607:Tablets
D002214:Capsules; D058607:Fibric Acids; D000960:Hypolipidemic Agents; D007202:Indicators and Reagents; D012997:Solvents; D013607:Tablets; D002995:Clofibric Acid; C019304:ciprofibrate; D015248:Gemfibrozil; D011345:Fenofibrate; D001629:Bezafibrate